Evidence map›Paper›PMID 27280630›Full record

ArticleBritish journal of cancer2016

Statin use and all-cancer survival: prospective results from the Women's Health Initiative.

Ange Wang, Aaron K Aragaki, Jean Y Tang, Allison W Kurian, JoAnn E Manson, Rowan T Chlebowski, Michael Simon, Pinkal Desai, Sylvia Wassertheil-Smoller, Simin Liu and 3 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Statins as Repurposed Drugs in Gynecological Cancer: A Review.International journal of molecular sciences · 2022
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Dysregulation of Cholesterol Homeostasis in Ovarian Cancer.Current oncology (Toronto, Ont.) · 2023
    Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Drug repurposing-an emerging strategy in cancer therapeutics.Naunyn-Schmiedeberg's archives of pharmacology · 2022
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Ange WangDepartment of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Aaron K AragakiDivision of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Jean Y TangDepartment of Dermatology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Allison W KurianDepartment of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA.
JoAnn E MansonDepartment of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Rowan T ChlebowskiLos Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA 90502, USA.
Michael SimonDepartment of Oncology, Karmanos Cancer Institute at Wayne State University, Detroit, MI 48344, USA.
Pinkal DesaiDepartment of Medicine, Weill Cornell Medical College, New York, NY 10065, USA.
Sylvia Wassertheil-SmollerDepartment of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
Simin LiuDepartment of Medicine, Brown University School of Medicine, Providence, RI 02903, USA.
Stephen KritchevskyWake Forest School of Medicine, Winston-Salem, NC 27157, USA.
Heather A WakeleeDepartment of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Marcia L StefanickDepartment of Medicine, Stanford Prevention Research Center, Stanford University School of Medicine, Stanford, CA 94305, USA.

Funding

NHLBI NIH HHS HHSN268201100001INHLBI NIH HHS HHSN268201100002INHLBI NIH HHS HHSN268201100004INHLBI NIH HHS HHSN268201100046CNIA NIH HHS HHSN271201100004CWHI NIH HHS HHSN268201100001CWHI NIH HHS HHSN268201100002CWHI NIH HHS HHSN268201100003CWHI NIH HHS HHSN268201100004C
6 · The paper itself

Abstract

backgroundThis study aims to investigate the association between statin use and all-cancer survival in a prospective cohort of postmenopausal women, using data from the Women's Health Initiative Observational Study (WHI-OS) and Clinical Trial (WHI-CT).

methodsThe WHI study enrolled women aged 50-79 years from 1993 to 1998 at 40 US clinical centres. Among 146 326 participants with median 14.6 follow-up years, 23 067 incident cancers and 3152 cancer deaths were observed. Multivariable-adjusted Cox proportional hazards models were used to investigate the relationship between statin use and cancer survival.

resultsCompared with never-users, current statin use was associated with significantly lower risk of cancer death (hazard ratio (HR), 0.78; 95% confidence interval (CI), 0.71-0.86, P<0.001) and all-cause mortality (HR, 0.80; 95% CI, 0.74-0.88). Use of other lipid-lowering medications was also associated with increased cancer survival (P-interaction (int)=0.57). The lower risk of cancer death was not dependent on statin potency (P-int=0.22), lipophilicity/hydrophilicity (P-int=0.43), type (P-int=0.34) or duration (P-int=0.33). However, past statin users were not at lower risk of cancer death compared with never-users (HR, 1.06; 95% CI, 0.85-1.33); in addition, statin use was not associated with a reduction of overall cancer incidence despite its effect on survival (HR, 0.96; 95% CI, 0.92-1.001).

conclusionsIn a cohort of postmenopausal women, regular use of statins or other lipid-lowering medications was associated with decreased cancer death, regardless of the type, duration, or potency of statin medications used.

Indexed as

AgedClinical Trials as TopicFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsIncidenceMiddle AgedNeoplasmsObservational Studies as TopicPostmenopauseProportional Hazards ModelsProspective StudiesRisk AssessmentRisk FactorsWomen's HealthHydroxymethylglutaryl-CoA Reductase Inhibitors

Identifiers

PMID27280630
PMCPMC4931370

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.